檢索結果 - Janet Wolter
- Showing 1 - 8 results of 8
-
1
-
2
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carci... 由 Aman U. Buzdar, Stephen E. Jones, Charles L. Vogel, Janet Wolter, Paul V. Plourde, Alan Webster
出版 1997Artigo -
3
-
4
-
5
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer p... 由 D. C. Tormey, R. Gray, Kennedy W. Gilchrist, Theodore Grage, Paul P. Carbone, Janet Wolter, Judith E. Woll, Frank J. Cummings
出版 1990Artigo -
6
-
7
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from... 由 Aman U. Buzdar, W. Jonat, Anthony Howell, Stephen E. Jones, Carl Blomqvist, Charles L. Vogel, W. Eiermann, Janet Wolter, Mark L. Steinberg, Alan Webster, David I. Lee
出版 1998Artigo -
8
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 由 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton
出版 2001Artigo
相關主題
Internal medicine
Medicine
Oncology
Breast cancer
Cancer
Chemotherapy
Tamoxifen
Adverse effect
Anastrozole
Cyclophosphamide
Gastroenterology
Megestrol
Megestrol acetate
Tolerability
Urology
Confidence interval
Gynecology
Hazard ratio
Surgery
Adjuvant
Anthracycline
Antiestrogen
Aromatase
Aromatase inhibitor
Bleomycin
Complication
Dacarbazine
Dermatology
Doxorubicin
Drug